Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 9Unknown 2Recruiting 2Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Prolactinoma 2Recurrence 1Pituitary Neoplasms 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Cabergoline × Clear all
NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Seoul National University Hospital

Phase NA Unknown
68 enrolled
Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

NCT01143584 2010-06-14

Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.

PIMERIndia

Phase NA Unknown
20 enrolled

Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡